Hacking Cancer's Hidden Switches: Philanthropy Bridges Global Divides

NEW YORK, NY – October 07, 2026 – In an era defined by fracturing global supply chains and the increasing siloing of national intellectual property, the lifeblood of scientific innovation—cross-border collaboration—is facing unprecedented headwinds. Yet, beneath the geopolitical friction, a different kind of capital is quietly moving to keep the international scientific community unified.

The Mark Foundation for Cancer Research today announced a $12 million investment across four multinational, cross-disciplinary scientific teams. Granted through its highly competitive Endeavor Awards program, this capital injection is purposefully designed to bypass rigid, localized funding frameworks. It unites leading minds from 11 premier academic institutions across five countries, equipping them to dismantle the mechanisms of invasive and treatment-resistant cancers.

Since its launch in 2021, the Endeavor Awards portfolio has grown to 15 grants totaling over $50 million. But beyond the impressive figures, this initiative highlights a critical shift in the global economy of science: as public funding bodies increasingly retreat within their own borders, private philanthropy is stepping into the void to underwrite the high-risk, high-reward collaborations that the modern world desperately needs.

Filling the Geopolitical Funding Void

The timing of this $12 million commitment is not incidental. The international scientific community is currently navigating a valley of death not just in commercialization, but in collaboration. Major cancer research funders have recently noted the chilling effects of geopolitical shifts—from post-Brexit bureaucracy in Europe to tightening federal budgets in the United States—on cross-border partnerships.

Public grants are frequently tied to domestic spending mandates, making it bureaucratically agonizing to fund a lab in Switzerland, a biophysicist in Austria, and an AI specialist in California under a single umbrella. By deploying an agile, international funding network, The Mark Foundation is acting as a crucial bridge. These three-year, $3 million grants offer scientists the financial freedom and operational flexibility to integrate distinct technologies, effectively bypassing the red tape that often stalls multidisciplinary breakthroughs.

Targeting the 'Undruggables' with AI and Biochemical Padlocks

Perhaps the most striking example of this borderless synergy is the BOLTS project (Blocking Oncogenic transcription via Ligand-Triggered SUMOylation). Spanning the AITHYRA Institute in Austria, EPFL in Switzerland, and Stanford University in the United States, this team is taking aim at one of oncology's most notorious challenges: overactivated transcription factors.

These master control switches drive aggressive tumor growth but have historically been deemed "undruggable." Unlike traditional targets, they lack the deep structural pockets necessary for conventional drugs to bind, and they constantly shift their shape. The prevailing logic in the burgeoning field of Targeted Protein Degradation (TPD) has been to find ways to entirely destroy these proteins.

However, the BOLTS project was born from an accidental discovery. Researchers analyzing a class of breast cancer drugs known as Selective Estrogen Receptor Degraders (SERDs) realized the drugs were not directly destroying their targets. Instead, they were triggering a natural cellular process called SUMOylation. This mechanism acts as a biochemical padlock, physically freezing the shape-shifting cancer switch onto the cell's DNA and rendering it silent.

Now, by uniting chemical biology, biophysics, and AI-enabled structural biology, the transatlantic team is building a pipeline to intentionally design new, drug-like padlocks. Rather than attempting to destroy elusive transcription factors, they aim to freeze them in an "off" state—a paradigm-shifting approach that could silence notorious drivers in treatment-resistant prostate, pancreatic, gastric, and brain cancers.

Dismantling the Shield: Unmasking Tumors to Immunotherapy

While the BOLTS team focuses on the structural mechanics of cancer cells, two other newly funded teams are investigating how tumors manipulate their environment to evade the human immune system.

Modern immunotherapies have revolutionized oncology, but they still fail a majority of patients with advanced gastric and esophageal cancers. A North Carolina-based team from UNC Chapel Hill and Duke University—co-funded by the Torrey Coast Foundation—has uncovered a critical piece of this puzzle. They discovered that high activity within a specific early-warning system inside tumor cells, known as the NLRP3 pathway, strongly predicts immunotherapy failure.

When this system activates, it acts as an invisibility cloak. It prevents the tumor from displaying the necessary molecular "flags" that immune cells look for and actively recruits immunosuppressive cells to guard the perimeter. Crucially, this genetic alteration is common across various aggressive solid tumors. Using advanced 3D models grown from patient cells, the team is testing new drugs designed to block this pathway, forcing the tumor to reveal itself and allowing the immune system to strike.

Simultaneously, a transatlantic consortium featuring researchers from Mount Sinai, Harvard, Columbia, and Ghent University is tackling the corruption of macrophages. Normally the body's frontline immune defenders, these specialized white blood cells are frequently hijacked by tumors to serve as protective shields.

The team recently overturned established assumptions by proving this corruption is a two-part assembly line. First, the tumor sends systemic signals through the bloodstream to alter how these immune cells are born in the bone marrow. Second, direct physical contact at the tumor site completes their transformation into deceptive allies. By combining human tumor profiling with functional genomics in mouse and zebrafish models, the team aims to intercept these signals and permanently rewrite the programming of these corrupted defenders, turning them back into potent tumor-killers. This work sits at the bleeding edge of immuno-oncology, running parallel to the broader industry's push toward engineered macrophage therapies.

Navigating the Metabolic Battlefield

The final endeavor highlights the profound intersection of global metabolic health trends and cancer progression. Of the 10 million people who die annually from cancer, roughly a quarter suffer from liver metastases. Researchers from VIB in Belgium and McGill University in Canada are investigating why these secondary tumors often adopt a deadly "replacement-type" growth pattern that physically weaves into existing liver tissue.

Their research points to a startling catalyst: fatty liver disease (steatosis). While cancer cells interacting with healthy liver tissue tend to form less aggressive, encapsulated clusters, a fatty liver environment encourages the cancer to switch into the highly lethal replacement form. For colorectal cancer patients, this shift drops the 5-year survival rate from 77% to less than 38%.

Using advanced cellular tracking and high-resolution imaging, the team is mapping the cellular conversations driven by this metabolic dysfunction. Their goal is to identify unique blind spots created by the liver's physical condition, paving the way for personalized therapies tailored to a patient's specific metabolic health.

As the global economy continues to grapple with fragmentation, the $12 million Endeavor Awards cohort serves as a powerful reminder of what is possible when capital is deployed strategically to erase borders. The path from laboratory discovery to active clinical treatment is fraught with immense biological complexity. The eradication of cancer will not be won by a single laboratory in a single country, but by the relentless, borderless pursuit of the science that connects them all.